AU2017355544A1 - Combination therapy of a T cell therapy and a BTK inhibitor - Google Patents
Combination therapy of a T cell therapy and a BTK inhibitor Download PDFInfo
- Publication number
- AU2017355544A1 AU2017355544A1 AU2017355544A AU2017355544A AU2017355544A1 AU 2017355544 A1 AU2017355544 A1 AU 2017355544A1 AU 2017355544 A AU2017355544 A AU 2017355544A AU 2017355544 A AU2017355544 A AU 2017355544A AU 2017355544 A1 AU2017355544 A1 AU 2017355544A1
- Authority
- AU
- Australia
- Prior art keywords
- cells
- inhibitor
- subject
- antigen
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 431
- 238000002659 cell therapy Methods 0.000 title claims abstract description 71
- 238000002648 combination therapy Methods 0.000 title claims abstract description 35
- 229940124291 BTK inhibitor Drugs 0.000 title claims description 67
- 210000004027 cell Anatomy 0.000 claims abstract description 349
- 239000003112 inhibitor Substances 0.000 claims abstract description 348
- 238000000034 method Methods 0.000 claims abstract description 270
- 239000000203 mixture Substances 0.000 claims abstract description 169
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 84
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 50
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 50
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 50
- 230000000694 effects Effects 0.000 claims abstract description 28
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 230000001965 increasing effect Effects 0.000 claims abstract description 9
- 230000002688 persistence Effects 0.000 claims abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 322
- 201000011510 cancer Diseases 0.000 claims description 285
- 239000000427 antigen Substances 0.000 claims description 251
- 108091007433 antigens Proteins 0.000 claims description 251
- 102000036639 antigens Human genes 0.000 claims description 251
- 102000042834 TEC family Human genes 0.000 claims description 162
- 108091082333 TEC family Proteins 0.000 claims description 162
- 238000011282 treatment Methods 0.000 claims description 154
- 102000005962 receptors Human genes 0.000 claims description 134
- 108020003175 receptors Proteins 0.000 claims description 134
- 230000000977 initiatory effect Effects 0.000 claims description 129
- 230000035772 mutation Effects 0.000 claims description 107
- -1 Ll-CAM Proteins 0.000 claims description 106
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 88
- 238000002560 therapeutic procedure Methods 0.000 claims description 88
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims description 86
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims description 86
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims description 79
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims description 78
- 229960001507 ibrutinib Drugs 0.000 claims description 78
- 230000004044 response Effects 0.000 claims description 72
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 64
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 64
- 210000004369 blood Anatomy 0.000 claims description 57
- 239000008280 blood Substances 0.000 claims description 57
- 230000005764 inhibitory process Effects 0.000 claims description 50
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 50
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 claims description 48
- 230000036210 malignancy Effects 0.000 claims description 48
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 42
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 42
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 42
- 108091000080 Phosphotransferase Proteins 0.000 claims description 40
- 108010075324 emt protein-tyrosine kinase Proteins 0.000 claims description 40
- 102000020233 phosphotransferase Human genes 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 38
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 36
- 102100026497 Zinc finger protein 654 Human genes 0.000 claims description 36
- 239000003814 drug Substances 0.000 claims description 35
- 229940124597 therapeutic agent Drugs 0.000 claims description 35
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 28
- 101001095088 Homo sapiens Melanoma antigen preferentially expressed in tumors Proteins 0.000 claims description 28
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 28
- 102100037020 Melanoma antigen preferentially expressed in tumors Human genes 0.000 claims description 28
- 102000003735 Mesothelin Human genes 0.000 claims description 28
- 108090000015 Mesothelin Proteins 0.000 claims description 28
- 102000004422 Phospholipase C gamma Human genes 0.000 claims description 28
- 108010056751 Phospholipase C gamma Proteins 0.000 claims description 28
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 28
- 208000008383 Wilms tumor Diseases 0.000 claims description 28
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 28
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 28
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 28
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 27
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 27
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 26
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 26
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims description 26
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 26
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 26
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 24
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 24
- 230000011664 signaling Effects 0.000 claims description 24
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 23
- 230000000638 stimulation Effects 0.000 claims description 23
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 22
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 22
- 210000001185 bone marrow Anatomy 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 108091008874 T cell receptors Proteins 0.000 claims description 21
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 21
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 20
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 20
- 230000027455 binding Effects 0.000 claims description 20
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 20
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 19
- 208000031404 Chromosome Aberrations Diseases 0.000 claims description 17
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 claims description 17
- 108700010039 chimeric receptor Proteins 0.000 claims description 17
- 230000000139 costimulatory effect Effects 0.000 claims description 17
- 208000037821 progressive disease Diseases 0.000 claims description 17
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 16
- 101150029707 ERBB2 gene Proteins 0.000 claims description 16
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 16
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 16
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 16
- 101710101516 Tyrosine-protein kinase TXK Proteins 0.000 claims description 16
- 210000001766 X chromosome Anatomy 0.000 claims description 16
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 16
- 230000037396 body weight Effects 0.000 claims description 16
- 210000000349 chromosome Anatomy 0.000 claims description 16
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 16
- 230000002519 immonomodulatory effect Effects 0.000 claims description 16
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 16
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 15
- 102100032912 CD44 antigen Human genes 0.000 claims description 15
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 15
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 15
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 15
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 15
- 229960004397 cyclophosphamide Drugs 0.000 claims description 15
- 229960000390 fludarabine Drugs 0.000 claims description 15
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 14
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 14
- 108700012439 CA9 Proteins 0.000 claims description 14
- 102000016736 Cyclin Human genes 0.000 claims description 14
- 108050006400 Cyclin Proteins 0.000 claims description 14
- 108010060273 Cyclin A2 Proteins 0.000 claims description 14
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 14
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims description 14
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims description 14
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 14
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims description 14
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 14
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims description 14
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 14
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 14
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims description 14
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 14
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims description 14
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims description 14
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims description 14
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims description 14
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 14
- 102100034256 Mucin-1 Human genes 0.000 claims description 14
- 102100023123 Mucin-16 Human genes 0.000 claims description 14
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 14
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 14
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 14
- 102100038081 Signal transducer CD24 Human genes 0.000 claims description 14
- 108010002687 Survivin Proteins 0.000 claims description 14
- 102100035721 Syndecan-1 Human genes 0.000 claims description 14
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims description 14
- 108091008605 VEGF receptors Proteins 0.000 claims description 14
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims description 14
- 230000003432 anti-folate effect Effects 0.000 claims description 14
- 229940127074 antifolate Drugs 0.000 claims description 14
- 239000000539 dimer Substances 0.000 claims description 14
- 230000009977 dual effect Effects 0.000 claims description 14
- 102000015694 estrogen receptors Human genes 0.000 claims description 14
- 108010038795 estrogen receptors Proteins 0.000 claims description 14
- 230000001605 fetal effect Effects 0.000 claims description 14
- 229940014144 folate Drugs 0.000 claims description 14
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 14
- 235000019152 folic acid Nutrition 0.000 claims description 14
- 239000011724 folic acid Substances 0.000 claims description 14
- 239000004052 folic acid antagonist Substances 0.000 claims description 14
- 208000002672 hepatitis B Diseases 0.000 claims description 14
- 102000006495 integrins Human genes 0.000 claims description 14
- 108010044426 integrins Proteins 0.000 claims description 14
- 230000004068 intracellular signaling Effects 0.000 claims description 14
- 102000003998 progesterone receptors Human genes 0.000 claims description 14
- 108090000468 progesterone receptors Proteins 0.000 claims description 14
- 230000007781 signaling event Effects 0.000 claims description 14
- 238000012360 testing method Methods 0.000 claims description 14
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 13
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 13
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 13
- 101150032879 Fcrl5 gene Proteins 0.000 claims description 12
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims description 12
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims description 12
- 230000004913 activation Effects 0.000 claims description 12
- 238000011469 lymphodepleting chemotherapy Methods 0.000 claims description 12
- 201000005787 hematologic cancer Diseases 0.000 claims description 11
- 238000000099 in vitro assay Methods 0.000 claims description 11
- 244000052769 pathogen Species 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 11
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 10
- 230000003915 cell function Effects 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000006870 function Effects 0.000 claims description 10
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 208000032839 leukemia Diseases 0.000 claims description 9
- 230000037361 pathway Effects 0.000 claims description 9
- 150000003384 small molecules Chemical group 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 108091023037 Aptamer Proteins 0.000 claims description 8
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 8
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 8
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 8
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 8
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 8
- 206010039491 Sarcoma Diseases 0.000 claims description 8
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 8
- 229960005305 adenosine Drugs 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000035578 autophosphorylation Effects 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 8
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 8
- 201000002528 pancreatic cancer Diseases 0.000 claims description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 230000004083 survival effect Effects 0.000 claims description 8
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 7
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 7
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 7
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 7
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 230000003071 parasitic effect Effects 0.000 claims description 6
- 230000009261 transgenic effect Effects 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 210000002865 immune cell Anatomy 0.000 claims description 5
- 230000019491 signal transduction Effects 0.000 claims description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 201000009030 Carcinoma Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims description 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 4
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 4
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 229940127121 immunoconjugate Drugs 0.000 claims description 4
- 230000003993 interaction Effects 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 3
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 230000003013 cytotoxicity Effects 0.000 claims description 3
- 231100000135 cytotoxicity Toxicity 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 210000004986 primary T-cell Anatomy 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 14
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 14
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 14
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 14
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 14
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 14
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 14
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 14
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 14
- 101150047061 tag-72 gene Proteins 0.000 claims 14
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 13
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 13
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 7
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 7
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 7
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 7
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 7
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 101150030213 Lag3 gene Proteins 0.000 claims 2
- 101100460850 Homo sapiens NCR3LG1 gene Proteins 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 75
- 238000009169 immunotherapy Methods 0.000 abstract description 15
- 238000011467 adoptive cell therapy Methods 0.000 abstract description 12
- 239000002955 immunomodulating agent Substances 0.000 abstract description 11
- 102000001253 Protein Kinase Human genes 0.000 abstract description 7
- 108060006633 protein kinase Proteins 0.000 abstract description 7
- 230000001976 improved effect Effects 0.000 abstract description 5
- 230000035755 proliferation Effects 0.000 abstract description 5
- 230000008685 targeting Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 101710120463 Prostate stem cell antigen Proteins 0.000 description 14
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 12
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 8
- 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 8
- 102100036841 C-C motif chemokine 1 Human genes 0.000 description 7
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 7
- 108010008707 Mucin-1 Proteins 0.000 description 7
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 7
- 102100038358 Prostate-specific antigen Human genes 0.000 description 7
- 101001039269 Rattus norvegicus Glycine N-methyltransferase Proteins 0.000 description 7
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 7
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 7
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 4
- 238000011357 CAR T-cell therapy Methods 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 4
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 description 4
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 description 4
- 102100033467 L-selectin Human genes 0.000 description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 3
- RRHONYZEMUNMJX-UHFFFAOYSA-N N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3-methylbutan-2-ylamino)methyl]benzamide Chemical compound C1=C(C(=O)N2CCN(CC2)C(C)=O)C(OC)=CC(C)=C1SC(S1)=CN=C1NC(=O)C1=CC=C(CNC(C)C(C)C)C=C1 RRHONYZEMUNMJX-UHFFFAOYSA-N 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010837 poor prognosis Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 102000006306 Antigen Receptors Human genes 0.000 description 2
- 108010083359 Antigen Receptors Proteins 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 description 2
- 101710092458 Lymphocyte activation gene 3 protein Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000004141 dimensional analysis Methods 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000013038 irreversible inhibitor Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 208000018555 lymphatic system disease Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002250 progressing effect Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 101150104237 Birc3 gene Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000707567 Homo sapiens Splicing factor 3B subunit 1 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100379220 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) API2 gene Proteins 0.000 description 1
- 102100031711 Splicing factor 3B subunit 1 Human genes 0.000 description 1
- 206010063092 Trisomy 12 Diseases 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000013413 tumor xenograft mouse model Methods 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417312P | 2016-11-03 | 2016-11-03 | |
| US62/417,312 | 2016-11-03 | ||
| US201662429735P | 2016-12-03 | 2016-12-03 | |
| US62/429,735 | 2016-12-03 | ||
| US201762574706P | 2017-10-19 | 2017-10-19 | |
| US62/574,706 | 2017-10-19 | ||
| PCT/US2017/060060 WO2018085731A2 (en) | 2016-11-03 | 2017-11-03 | Combination therapy of a t cell therapy and a btk inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017355544A1 true AU2017355544A1 (en) | 2019-05-16 |
Family
ID=60515805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017355544A Abandoned AU2017355544A1 (en) | 2016-11-03 | 2017-11-03 | Combination therapy of a T cell therapy and a BTK inhibitor |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190298772A1 (enExample) |
| EP (1) | EP3534938A2 (enExample) |
| JP (2) | JP2019532997A (enExample) |
| CN (1) | CN110139669A (enExample) |
| AU (1) | AU2017355544A1 (enExample) |
| CA (1) | CA3042049A1 (enExample) |
| MA (1) | MA46783A (enExample) |
| MX (2) | MX2019005029A (enExample) |
| WO (1) | WO2018085731A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| CA3061945A1 (en) * | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
| KR20200054160A (ko) | 2017-06-02 | 2020-05-19 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료를 위한 물품 제조 및 방법 |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
| MX2021005366A (es) | 2018-11-08 | 2021-09-10 | Juno Therapeutics Inc | Metodos y combinaciones para el tratamiento y modulacion de celulas t. |
| CN113164408B (zh) * | 2018-12-07 | 2025-07-22 | 克莱格医学有限公司 | 肿瘤联合免疫治疗 |
| WO2021020846A1 (en) | 2019-07-26 | 2021-02-04 | Abl Bio Inc. | Anti-her2/anti-4-1bb bispecific antibody and use thereof |
| EP4055383A1 (en) | 2019-11-05 | 2022-09-14 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| US20230138309A1 (en) * | 2020-03-20 | 2023-05-04 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| US20240293365A1 (en) * | 2021-06-28 | 2024-09-05 | The Regents Of The University Of California | Methods for treating and ameliorating t cell related diseases |
| US20250345432A1 (en) | 2022-05-25 | 2025-11-13 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2025137059A1 (en) * | 2023-12-18 | 2025-06-26 | Corvus Pharmaceuticals, Inc. | Use of itk inhibitors and car t-cell therapy |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ATE114507T1 (de) | 1988-12-28 | 1994-12-15 | Stefan Miltenyi | Verfahren sowie materialien zur hochgraduierten magnetischen abspaltung biologischer materialien. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| DK1066380T3 (da) | 1998-05-19 | 2002-01-28 | Avidex Ltd | Opløselig T-cellereceptor |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| HUP0303538A2 (hu) | 2000-12-21 | 2005-02-28 | Bristol-Myers Squibb Co. | Tirozin kinázok Tec családjának tiazolil-vegyület inhibitorai és ezeket tartalmazó gyógyszerkészítmények |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| JP4317940B2 (ja) | 2001-08-31 | 2009-08-19 | イミュノコア・リミテッド | 物質 |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| SE0202461D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| US7569664B2 (en) | 2002-10-09 | 2009-08-04 | Immunocore Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| MY144339A (en) | 2003-09-08 | 2011-08-29 | Aventis Pharma Inc | Thienopyrazoles |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| US20050209284A1 (en) | 2004-02-12 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tec kinase inhibitors |
| JP5563194B2 (ja) | 2004-06-29 | 2014-07-30 | イムノコア リミテッド | 改変ｔ細胞レセプターを発現する細胞 |
| US8101770B2 (en) | 2004-12-16 | 2012-01-24 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
| WO2007016977A1 (de) | 2005-08-05 | 2007-02-15 | Delica Ag | Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel |
| WO2007027594A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| EP1957491A2 (en) | 2005-11-12 | 2008-08-20 | Boehringer Ingelheim International GmbH | Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| CA2651732C (en) | 2006-05-18 | 2014-10-14 | Mannkind Corporation | Intracellular kinase inhibitors |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| CA2662074A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| EP2526934B1 (en) | 2006-09-22 | 2015-12-09 | Pharmacyclics LLC | Inhibitors of bruton's tyrosine kinase |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| JP5600063B2 (ja) | 2007-10-19 | 2014-10-01 | セルジーン アビロミクス リサーチ， インコーポレイテッド | ヘテロアリール化合物およびその使用 |
| EP3338895B1 (en) | 2007-12-07 | 2022-08-10 | Miltenyi Biotec B.V. & Co. KG | Sample processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| EP2361248B1 (en) | 2008-06-27 | 2018-09-19 | Celgene CAR LLC | Heteroaryl compounds and uses thereof |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| WO2011017219A1 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Imidazoquinoxalinones and anti-tumor treatment |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| NZ604040A (en) | 2010-06-03 | 2015-02-27 | Pharmacyclics Inc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| JP6368243B2 (ja) | 2011-11-11 | 2018-08-08 | フレッド ハッチンソン キャンサー リサーチ センター | がんのためのサイクリンａ１に標的化されたｔ細胞免疫療法 |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2665548C2 (ru) | 2012-05-03 | 2018-08-30 | Фред Хатчинсон Кансэр Рисёч Сентер | Способ получения клеток, экспрессирующих т-клеточный рецептор |
| EA201492082A1 (ru) | 2012-06-04 | 2015-03-31 | Фармасайкликс, Инк. | Кристаллические формы ингибитора тирозинкиназы брутона |
| PL2884999T3 (pl) * | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| EA201590822A1 (ru) | 2012-11-02 | 2016-01-29 | Фармасайкликс, Инк. | Адъювантная терапия ингибитором киназы семейства tec |
| WO2014082085A1 (en) | 2012-11-26 | 2014-05-30 | The University Of North Carolina At Chapel Hill | Use of itk inhibitors for the treatment of cancer |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| US9405601B2 (en) | 2012-12-20 | 2016-08-02 | Mitsubishi Electric Corporation | In-vehicle apparatus and program |
| US9499519B2 (en) | 2012-12-26 | 2016-11-22 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| KR101871561B1 (ko) | 2013-03-15 | 2018-06-27 | 난트바이오사이언스 인코포레이티드 | 치환된 인돌-5-올 유도체와 그들의 치료적 용도 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| HRP20201906T1 (hr) | 2013-12-20 | 2021-04-02 | Fred Hutchinson Cancer Research Center | Označene kimerne efektorske molekule i njihovi receptori |
| FI3888674T3 (fi) * | 2014-04-07 | 2024-07-02 | Novartis Ag | Syövän hoito käyttäen kimeeristä anti-cd19-antigeenireseptoria |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| MA46995A (fr) * | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
-
2017
- 2017-11-03 MX MX2019005029A patent/MX2019005029A/es unknown
- 2017-11-03 WO PCT/US2017/060060 patent/WO2018085731A2/en not_active Ceased
- 2017-11-03 MA MA046783A patent/MA46783A/fr unknown
- 2017-11-03 EP EP17807967.9A patent/EP3534938A2/en not_active Withdrawn
- 2017-11-03 CN CN201780082035.6A patent/CN110139669A/zh active Pending
- 2017-11-03 AU AU2017355544A patent/AU2017355544A1/en not_active Abandoned
- 2017-11-03 CA CA3042049A patent/CA3042049A1/en active Pending
- 2017-11-03 JP JP2019523665A patent/JP2019532997A/ja not_active Withdrawn
- 2017-11-03 US US16/346,528 patent/US20190298772A1/en not_active Abandoned
-
2019
- 2019-04-29 MX MX2023004707A patent/MX2023004707A/es unknown
-
2023
- 2023-06-23 JP JP2023103197A patent/JP2023120386A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3534938A2 (en) | 2019-09-11 |
| CA3042049A1 (en) | 2018-05-11 |
| MX2019005029A (es) | 2019-10-24 |
| WO2018085731A3 (en) | 2018-07-12 |
| CN110139669A (zh) | 2019-08-16 |
| MX2023004707A (es) | 2023-05-09 |
| JP2019532997A (ja) | 2019-11-14 |
| JP2023120386A (ja) | 2023-08-29 |
| WO2018085731A2 (en) | 2018-05-11 |
| MA46783A (fr) | 2019-09-11 |
| US20190298772A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250186503A1 (en) | Methods and combinations for treatment and t cell modulation | |
| JP7299841B2 (ja) | 細胞療法と免疫調節化合物の併用 | |
| US20240368625A1 (en) | Methods and compositions for preparing genetically engineered cells | |
| US20240016840A1 (en) | Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors | |
| US20190298772A1 (en) | Combination therapy of a t cell-based therapy and a btk inhibitor | |
| JP2023025191A (ja) | 細胞療法とガンマセクレターゼ阻害剤との組み合わせ | |
| JP7275104B2 (ja) | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 | |
| CN113474450A (zh) | 产生工程化细胞的方法以及所述工程化细胞的组合物 | |
| RU2795454C2 (ru) | Способы и композиции для получения генно-инженерных клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |